Medytox sets up U.S. subsidiary Luvantas

Thomas Albright [Courtesy of Medytox]

South Korea’s Medytox Inc. announced Wednesday that it established a U.S. subsidiary Luvantas and named Thomas Albright, a former Allergan executive, to lead the unit.

Luvantas, fully owned by Medytox, has been set up in Irvine, California, with a strategic aim to manage local operations and spearhead the marketing initiatives for MT10109L, a non-animal-derived liquid toxin formulation, in the U.S. and Canada.

The subsidiary will be responsible for overseas markets for hyaluronic acid filler Neuramis and derma-cosmetics Neuraderm from Medytox.

As the former head of global marketing strategy for Allergan’s botulinum toxin Botox, Albright led the successful launch of Botox.

He also contributed to the development of new therapeutic indications for Botox and the R&D of next-generation biologics.

Medytox expects his knowledge of the global aesthetic treatment market to help build a localized direct sales force and lead a successful U.S. launch of MT10109L, which is targeted for marketing approval in 2025.